Vir Biotechnology, Inc. (NASDAQ:VIR) Holdings Raised by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its position in Vir Biotechnology, Inc. (NASDAQ:VIR) by 10.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,252,655 shares of the company’s stock after acquiring an additional 118,379 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.91% of Vir Biotechnology worth $9,194,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. bought a new position in Vir Biotechnology during the 4th quarter worth $60,000. KBC Group NV grew its stake in Vir Biotechnology by 136.5% during the 4th quarter. KBC Group NV now owns 8,970 shares of the company’s stock worth $66,000 after buying an additional 5,177 shares during the last quarter. CIBC Asset Management Inc bought a new position in Vir Biotechnology during the 4th quarter worth $74,000. Captrust Financial Advisors bought a new position in Vir Biotechnology during the 3rd quarter worth $118,000. Finally, Quarry LP grew its stake in Vir Biotechnology by 901.8% during the 3rd quarter. Quarry LP now owns 17,000 shares of the company’s stock worth $127,000 after buying an additional 15,303 shares during the last quarter. 65.32% of the stock is currently owned by institutional investors.

Vir Biotechnology Stock Up 0.9 %

Shares of VIR stock opened at $6.93 on Friday. The stock has a 50-day simple moving average of $9.15 and a 200 day simple moving average of $8.39. Vir Biotechnology, Inc. has a fifty-two week low of $6.56 and a fifty-two week high of $14.45. The stock has a market capitalization of $950.40 million, a P/E ratio of -1.77 and a beta of 1.17.

Vir Biotechnology (NASDAQ:VIR) last announced its earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.09. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The business had revenue of $12.37 million during the quarter, compared to analysts’ expectations of $8.14 million. On average, sell-side analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Insider Activity at Vir Biotechnology

In related news, EVP Verneuil Vanina De sold 7,373 shares of the stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total value of $67,389.22. Following the completion of the transaction, the executive vice president now owns 79,460 shares in the company, valued at $726,264.40. This trade represents a 8.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director George A. Scangos sold 10,964 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $9.81, for a total value of $107,556.84. Following the completion of the transaction, the director now owns 708,295 shares of the company’s stock, valued at $6,948,373.95. This trade represents a 1.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,859 shares of company stock valued at $326,458 over the last 90 days. 15.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on VIR. HC Wainwright restated a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a research note on Friday, February 28th. Barclays raised their price target on Vir Biotechnology from $26.00 to $31.00 and gave the company an “overweight” rating in a report on Friday, February 28th. Leerink Partners raised their price target on Vir Biotechnology from $18.00 to $20.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Morgan Stanley raised Vir Biotechnology from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $10.00 to $20.00 in a report on Thursday, January 9th. Finally, Needham & Company LLC reissued a “buy” rating and set a $19.00 price target on shares of Vir Biotechnology in a report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Vir Biotechnology currently has a consensus rating of “Moderate Buy” and an average target price of $35.67.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).